Compare · Research-Use-Only

Compare research peptides

Side-by-side mechanism, molecular spec, and published-research comparisons. Pick a matchup below or browse the full catalog.

BPC-157 vs GHK-Cu

The two most-cited recovery peptides. BPC-157 modulates growth factor pathways; GHK-Cu is a copper chaperone influencing collagen synthesis.

Single GH secretagogue vs the combined pulse plus extended half-life pairing, and when the addition of CJC-1295 changes the protocol.

Dual GIP/GLP-1 agonist (Tirzepatide, SURMOUNT-1) versus the triple-agonist Retatrutide with added glucagon receptor activity (Phase 2, NEJM).

GHRH analog vs ghrelin-mimetic. Different upstream targets, overlapping downstream GH and IGF-1 effects in research models.

The classic recovery pairing, and the most frequently confused. Growth factor modulation vs actin sequestration, plus what TB-500 actually is.

DAC vs no-DAC is not a formulation detail, it is a different molecule. Days-long albumin binding vs an hours-long pulsatile profile.

Incretin agonism vs amylin analog. Different pathways, which is why they are studied together rather than head-to-head.

Grouped constantly, mechanistically unrelated. ACTH fragment and neurotrophin expression vs tuftsin derivative and GABAergic modulation.

Both appear in longevity research, with very different evidence bases. Telomerase induction from a narrow literature vs a core metabolic cofactor.

A GH fragment that missed its Phase IIb endpoint vs a small-molecule NNMT inhibitor that is not a peptide. Read the evidence carefully on both.

Request a side-by-side in our Discord community. We add new comparisons based on what researchers ask about most.